Study Design
emesis, NPC; stage II, CINV, Cancer
DISEASE, CANCER
This open-label, prospective, pilot randomized clinical trial was approved by the ethical committee of Sun Yat-Sen University Cancer Center. This study was investigator initiated and conducted at a single institution. Written informed consent was obtained from all patients. This study followed the Consolidated Standards of Reporting Trials (The inclusion criteria were previously untreated, histologically confirmed nonkeratinizing NPC; stage II to IVa disease (according to the American Joint Committee on Cancer classification system, eighth edition); achieved CINV control (defined as no emesis and no rescue therapy during the first 120 hours after initiation of chemotherapy) using fosaprepitant-based regimens after 2 to 3 cycles of induction chemotherapy; scheduled to receive IMRT and concomitant cisplatin every 3 weeks at 100 mg/mEligible patients were enrolled after induction chemotherapy. Patients were then randomized 1:1 to receive either fosaprepitant weekly or every 3 weeks during CCRT, with a block size of 6 (known only to the data management team). Random assignment was performed by sealed envelopes at the Clinical Trials Centre of Sun Yat-sen University Cancer Centre, with a computer-generated random number code. Treatment group assignment was not masked.